Abstract PO3-23-03: Radar reflectors for marking of target lymph nodes in patients receiving neoadjuvant chemotherapy for breast cancer – a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial
Authors: Banys-Paluchowski Maggie , Hartmann Steffi , de Boniface Jana , Gentilini Oreste Davide , Basali Timo , Stickeler Elmar , Untch Michael , Ruf Franziska , Fröhlich Sarah , Thill Marc , Lux Michael P. , Peintinger Florentia , Cakmak Guldeniz Karadeniz , Rubio Isabel , Kontos Michalis , Micco Rosa Di , Murawa Dawid , Schlichting Ellen , Sezen Bilge Aktas , Rody Achim , Langanke Dagmar , Bündgen Nana , Sanchez-Mendez Jose Ignacio , Buss-Steidle Renu , Mau Christine , Buchmann Nana , Riemer Sabine , Hansen Marit Helene , Ditsch Nina , Kühn Thorsten 
Published: May 2024

Background:

Surgical staging procedures of the axilla in breast cancer patients converting from a clinically positive (cN+) to a clinically negative (ycN0) lymph node status during neoadjuvant chemotherapy (NACT) vary across countries and within individual countries. The international prospective AXSANA (EUBREAST-03) study aims at comparatively evaluating long-term outcomes of different staging procedures such as axillary lymph node dissection (ALND), sentinel lymph node biopsy (SLNB), target lymph node biopsy (TLNB) and targeted axillary dissection (TAD). The comparison of marking techniques for the target lymph node (TLN) is a secondary endpoint. In this subgroup analysis, we report on the largest yet prospective cohort of patients receiving a radar reflector for marking of the TLN prior to NACT. Methods:

The AXSANA study is an international prospective cohort study including cN+ patients converting to ycN0 status and treated with different axillary staging techniques according to the standard at their treating institution. The study was initiated by the EUBREAST network and started enrollment in August 2020. Eligible patients have cT1-4c tumors, initially present with axillary lymph node metastasis and receive neoadjuvant chemotherapy. Patients converting to ycN0 status are followed up for 5 years irrespectively of the ypN status. In the present subgroup analysis, only patients with a TLN marked by a radar reflector were included. We prospectively examined the retrieval rate of radar reflectors and the identification rate of the TLN (defined as unequivocal removal of the lymph node, i.e., the presence of lymphatic tissue in the TLN specimen and/or pathological confirmation of post-NACT changes typical for metastatic lymph nodes responding to treatment). Results:

A TLN was marked using a radar reflector in 74 patients prior to NACT. The median age was 52 years (range: 32-77). The most common subtype was no special type in 68 (92%) patients and invasive lobular cancer in 7 (7%) patients. Most patients (n = 44, 59%) had one suspicious node at time of diagnosis, followed by two (n = 15, 20%), three (n = 10, 14%) or ≥ four suspicious nodes (n = 5, 5%). Only one TLN was marked in 73 (99%) patients and two nodes were marked in one patient (1%). Fifteen patients (20%) had a MRI between marker placement and surgery. In 4 out of 15 cases (27%), MRI artifacts were described. However, the assessment of MRI was limited due to artifacts only in one out of these four patients (25%). Out of the 74 patients with radar reflector marked TLN, 45 (61%) had undergone final surgery at the time of analysis and 29 (39%) are still under NACT. 36 out of 45 patients (80%) who received final surgery converted to ycN0. Most patients had undergone a TAD (n = 41, 91%), followed by TLNB in 7% (n = 3) and upfront ALND in 2% of cases (n = 1). All radar reflectors were successfully removed. In 44 out of 45 patients (98%) the TLN was unequivocally identified and removed. In one patient the tissue specimen containing radar reflector consisted of fat tissue and no lymphatic tissue was identifiable, so it remains unclear whether the TLN was excised, or the reflector might have dislocated. 29 patients (65%) had converted to ypN0 status. Conclusion:

To the best of our knowledge this is the largest prospective series of patients receiving a radar reflector for the marking of TLN prior to NACT for breast cancer. The removal rate of the marker and the detection rate of the target node were very high. Our data demonstrate that radar reflectors are a reliable tool for marking of target lymph nodes before neoadjuvant treatment.

Citation Format: Maggie Banys-Paluchowski, Steffi Hartmann, Jana de Boniface, Oreste Davide Gentilini, Timo Basali, Elmar Stickeler, Michael Untch, Franziska Ruf, Sarah Fröhlich, Marc Thill, Michael P. Lux, Florentia Peintinger, Guldeniz Karadeniz Cakmak, Isabel Rubio, Michalis Kontos, Rosa Di Micco, Dawid Murawa, Ellen Schlichting, Bilge Aktas Sezen, Achim Rody, Dagmar Langanke, Nana Bündgen, Jose Ignacio Sanchez-Mendez, Renu Buss-Steidle, Christine Mau, Nana Buchmann, Sabine Riemer, Marit Helene Hansen, Nina Ditsch, Thorsten Kühn. Radar reflectors for marking of target lymph nodes in patients receiving neoadjuvant chemotherapy for breast cancer – a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO3-23-03.